CEL-SCI Regains Listing Compliance with NYSE MKT

Business Wire

VIENNA, Va.--(BUSINESS WIRE)--

CEL-SCI Corporation (NYSE MKT:CVM) today announced that it has received notification from NYSE Regulation dated October 17, 2013 that the Company is now considered to have regained compliance with the listing requirements of the NYSE MKT LLC (the “Exchange”) Company Guide.

The Company previously received notice from the Exchange on July 18, 2013, indicating that the Company is not in compliance with Section 1003(a)(iv) of the Exchange's continued listing standards.

The Exchange also indicated that as is the case for all listed issuers, the Company’s continued listing eligibility will continue to be assessed on an ongoing basis.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. The lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI entered into a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. It has also announced that it entered into a co-development agreement with Ergomed to further develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV. CEL-SCI is also investigating a different peptide-based immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu (See Journal of Clinical Investigation – J Clin Invest. 2013; 123(7):2850-2861. doi: 10.1172/JCI67550) Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2012. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
View Comments